Regeneron Pharmaceuticals, Inc.
看多

REGN trend reversal and 30% upside

281
Recently, REGN has been in a downtrend. As supported by the technical indicators, there seems to be a potential trend reversal with a potential upside of 30% as evidenced by the oversold RSI level of <30 and a potential bullish divergence. A LONG initiated at or near $460 PS supported by near fib retracement level indicates 30% upside with the upside target of $600 and downside bearish target of $398 over the next quarter.

The technicals are also supported fundamentally by strong revenue growth of 30% Y/Y and a P/E of ~15 which is abnormally low for the stock. With the strong projected growth and multiple upcoming catalysts for the stock, it poses a unique opportunity for both mid-term and long-term investors. Furthermore, analyst consensus converges to mid $700.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。